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Rapamycin and chronic kidney 
disease: beyond the inhibition of 
inflammation
Y Liu1
Rapamycin, a potent inhibitor of the mammalian target of rapamycin 
(mTOR) protein kinase, is a well-known immunosuppressive agent. 
In this issue, Wu and colleagues report that rapamycin significantly 
attenuates renal interstitial fibrosis in obstructive nephropathy. 
Besides its inhibition of renal inflammation, rapamycin is able to 
block tubular epithelial-mesenchymal transition, thereby shedding 
new light on the mechanism of its antifibrotic actions.
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Much has been documented in the litera-
ture about the importance of renal inter-
stitial lesions in the evolution of chronic 
kidney diseases progressing to end-stage 
renal failure.1 However, our options for 
therapeutic interventions aimed at reduc-
ing renal interstitial fi brosis in the clini-
cal setting remain scarce. Although the 
introduction of angiotensin-converting 
enzyme inhibitors and angiotensin recep-
tor blockers into the standard treatment 
regimen for chronic kidney diseases in 
past decade can be considered a remark-
able success, these agents seldom com-
pletely halt the progressive loss of renal 
function. In this context, developing 
additional and/or new intervention stra-
tegies that prevent or inhibit interstitial 
fi brogenesis continues to be a principal 
therapeutic goal in renal medicine.
Rapamycin is best known to nephrol-
ogists as a potent immunosuppressant 
that is presently used clinically in renal 
transplantation. It was originally iden-
tifi ed three decades ago on the basis of 
its antifungal property.2 Th e study of its 
mechanism of action has led to the tri-
umphant discovery of a complex intra-
cellular signaling network in which 
the mammalian target of rapamycin 
(mTOR) is a central component. mTOR 
is an evolutionarily conserved, ubiqui-
tously expressed, intracellular serine/
threonine protein kinase that plays a 
key role in regulating cell proliferation 
and organ growth by controlling many 
cellular processes, such as translation, 
transcription, ribosomal biogenesis, 
metabolism, and cell cycle progression. 
Activation of mTOR leads to the phos-
phorylation of its two well-characterized 
downstream eff ectors, p70 ribosomal 
S6 kinase (p70S6K) and eukaryotic 
initiation factor-4E-binding protein-1 
(4E-BP1), thereby promoting RNA and 
protein synthesis (Figure 1). In addi-
tion, mTOR-activated p70S6K, via cyc-
lin-dependent kinases (cdks), promotes 
cell cycle progression (Figure 1).
Like many other important signal 
pathways, the mTOR signaling net-
work is very complex, with multiple 
cross-talks and feedback mechanisms. 
Aberrant regulation of mTOR signaling 
is associated with various human dis-
eases, including cancer and cardiovas-
cular disorders.3 As a result, mTOR has 
become an attractive target for antican-
cer therapy, and numerous clinical trials 
using rapamycin or its derivatives have 
been initiated in several tumor types, 
including renal-cell carcinoma, breast 
carcinoma, and non-small-cell lung car-
cinoma.3 Likewise, clinical trials have 
shown that rapamycin has long-term 
benefi ts in preventing restenosis of coro-
nary arteries aft er angio plasty,4 an eff ect 
presumably related to the downregula-
tion of infl ammation and fi brosis.
As for the kidney, rapamycin has been 
successfully used as an immunosuppres-
sive agent in renal transplantation, oft en 
in combination with other anti-infl am-
matory drugs such as cyclosporine or 
mycophenolate mofetil. Rapamycin, 
once it enters the cell, binds to a cyto-
plasmic receptor, FK506-binding pro-
tein-12. This drug–receptor complex 
then interacts with mTOR and perturbs 
its function, causing an arrest of the cell 
cycle at the G1 phase. Th e eff ectiveness 
of rapamycin as an immunosuppressant 
is illustrated by its ability to suppress T- 
and B-cell activation, proliferation, and 
clonal expansion. Th rough mTOR inhibi-
tion, rapamycin is able to block the inter-
leukin-2-dependent activation of p70S6K 
and T-cell mitogenesis and induces 
dendritic-cell apoptosis by interfering 
with granulocyte–macrophage colony-
stimulating factor signaling. In essence, 
rapamycin not only inhibits T-cell acti-
vation directly but also diminishes the 
population of dendritic cells that present 
antigen to T cells during activation.5
On the basis of its antiproliferative 
property in many cell types, including 
tubular epithelial cells,6 rapamycin has 
been recently tested in experimental 
kidney diseases in which abnormal cell 
proliferation is a predominant patho-
logic feature. An interesting study from 
Edelstein’s group has demonstrated that 
rapamycin is effective in slowing the 
progression of polycystic kidney dis-
ease in a rat model.7 Administration of 
rapamycin inhibits renal enlargement 
and cystogenesis and prevents the loss of 
kidney function in vivo, presumably by 
its ability to inhibit cell proliferation in 
cystic and non-cystic tubules.7 Similarly, 
activated mTOR signaling is also linked 
to the evolution of renal hypertrophy 
due to compensatory growth aft er the 
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loss of functioning nephrons, a charac-
teristic feature of many chronic kidney 
diseases.8,9 For instance, in the remain-
ing kidney aft er unilateral nephrectomy, 
increased phosphorylation of p70S6K 
and 4E-BP1 is found; and rapamycin 
blocks the unilateral-nephrectomy-
induced p70S6K and 4E-BP1 phosphory-
lation and prevents renal hypertrophy.8 
Rapamycin has also been demonstrated 
to attenuate proteinuria-associated tubu-
lointerstitial infl ammation and fi brosis 
in experimental membranous nephropa-
thy,9 as well as in chronic allograft  neph-
ropathy. Together, these fi ndings have 
begun to authenticate mTOR signaling 
as a potential target for therapeutic inter-
vention in chronic kidney diseases.
In this issue, Wu and colleagues spe-
cifi cally explore the question of whether 
rapamycin has a therapeutic role in 
slowing the progression of renal inter-
stitial fi brosis induced by unilateral ure-
teral obstruction, a widely used fi brosis 
model characterized by inflammatory 
infi ltration, tubular dilatation, intersti-
tial expansion, and matrix deposition.10 
The authors show that rapamycin was 
capable of blunting the enlargement of 
the obstructed kidney, reducing tubular 
dilatation and interstitial volume, and 
inhibiting α-smooth muscle actin expres-
sion and interstitial collagen deposition. 
Furthermore, rapamycin decreased the 
infiltration of inflammatory cells and 
inhibited renal transforming growth 
factor-β1 (TGFβ1) expression. In short, 
these data demonstrate that rapamycin is 
renal protective, resulting in signifi cant 
amelioration of renal interstitial infl am-
mation and fi brosis.
The beneficial effects of rapamycin 
may potentially be mediated by mul-
tiple mechanisms. Th rough inhibition 
of mTOR signaling, rapamycin might 
eff ectively block the increased protein 
synthesis and cell cycle progression in 
the obstructed kidney; this probably 
accounts for its inhibitory eff ects on renal 
hypertrophy and inflammation. The 
ability of rapamycin to inhibit TGFβ1 
expression in vivo also provides a signifi -
cant insight into its antifi brotic action. 
Perhaps one of the most interesting 
fi ndings of Wu et al.10 is that rapamycin 
was able to block tubular epithelial-to-
mesenchymal transition (EMT), as dem-
onstrated by partial restoration of the 
E-cadherin expression and inhibition 
of the de novo expression of α-smooth 
muscle actin in cultured tubular epithe-
lial cells aft er TGFβ1 stimulation. Tubu-
lar EMT is a cell phenotypic conversion 
process that has been increasingly recog-
nized to play a major role in the patho-
genesis of renal interstitial fibrosis.11 
Th e observation of rapamycin blockade 
of tubular EMT virtually establishes an 
intimate connection between mTOR sig-
naling and the EMT program. In sup-
port of this notion, a recent report also 
demonstrates that rapamycin inhibits 
the expression of Snail (Figure 1), a key 
transcription factor that plays an impor-
tant role in suppressing E-cadherin, 
and blocks EMT in cultured human 
peritoneal mesothelial cells.12 Th erefore, 
the action of rapamycin clearly goes 
beyond the inhibition of infl ammation, 
and it could directly interfere with EMT, 
one of the central events in renal 
interstitial fi brogenesis.
Like any scientifi c inquiry, the present 
study generates new questions to be 
answered. One uncertainty is whether 
all the benefi cial eff ects of rapamycin 
are mediated by inhibition of mTOR sig-
naling. Th e dose of rapamycin used in 
this study was signifi cantly higher than 
that necessary for inhibition of mTOR 
in rats,7,9 raising the possibility that 
rapamycin may elicit some of its eff ects 
by an mTOR-independent mechanism. 
Another issue is that we do not know 
the relative contribution of the diff er-
ent actions of rapamycin to its overall 
benefi ts in the fi brotic kidney. Further-
more, the signifi cance of the inhibition 
of compensatory kidney growth by 
rapamycin in relation to its antifi brotic 
ability is unclear at this stage, because 
it could be benefi cial or detrimental in 
terms of preserving renal structure and 
function. Finally, the inhibitory eff ect of 
rapamycin on TGFβ1 expression appears 
to be controversial, as an earlier study 
shows that it induces TGFβ1 expression 
and potentiates chronic cyclosporine 
nephropathy.13 Clearly, more studies 
are warranted to confi rm the antifi brotic 
effi  cacy of rapamycin in diff erent animal 
models and to elucidate the mechanism 
of its actions.
Renal interstitial fi brosis is oft en con-
sidered the fi nal outcome of all chronic 
kidney diseases; hence, any therapeu-
tic intervention that works is urgently 
needed. In this regard, exploiting the 
antifibrotic potential of the approved 
drugs that are presently used clinically 
for a different purpose will be espe-
cially appealing. In view of the ability of 
Figure 1 | Potential actions of rapamycin in chronic renal fibrosis. Mammalian target of 
rapamycin (mTOR), through its downstream effectors, plays a critical role in regulating a variety 
of cellular processes, such as cell proliferation and hypertrophy, T-cell infiltration and clonal 
expansion, and tubular epithelial-to-mesenchymal transition (EMT). Arrows represent activation, 
and bars represent inhibition. p70S6K, p70 ribosomal S6 kinase; 4E-BP1, eukaryotic initiation 
factor-4E-binding protein-1; eIF-4E, eukaryotic initiation factor-4E; cdk, cyclin-dependent kinase.
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rapamycin to inhibit both infl ammation 
and fi brosis, rapamycin and its deriva-
tives may hold promise as new additions 
to the armamentarium in our fights 
against chronic kidney fi brotic diseases.
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Tools to detect and modify sickle 
cell nephropathy
JI Scheinman1
Placement of the development of a sickle cell nephropathy in a 
time/event line is helped by better measures of glomerular filtration 
rate, tubular dysfunction, and proteinuria. Preventing or slowing the 
nephropathy can improve the outcome of this complication of the 
devastating sickle cell disease.
Kidney International (2006) 69, 1927–1930. doi:10.1038/sj.ki.5000412
A major thrust in nephrology has been 
the development of guidelines for improv-
ing global outcomes of kidney disease 
(http://www.Doqi.org). Delaying kidney 
failure is especially important when the 
risk is higher, as in diabetes mellitus and 
sickle cell disease, which carry a risk of 
serious chronic kidney disease as high as 
25%.1 Far more than in other diseases, 
when kidney failure occurs in sickle cell 
disease, the treatment chosen by patient 
and physician is likely to be dialysis, a 
functionally and economically poorer 
choice than transplantation.1
As they report in the current issue, 
Voskaridou et al.2 studied 87 subjects with 
sickle cell/β-thalassemia to learn whether 
renal damage and progressive kidney dis-
ease can be detected earlier by better meas-
ures of renal function (with cystatin-C 
levels greater than 0.96 mg per liter) and 
markers of tubular damage (with serum 
β2-microglobulin levels greater than 
1.8 mg per liter and urinary N-acetyl-
β-d-glucosaminidase levels greater than 
2 units per day), compared with creati-
nine (CR) clearance alone (less than 80 ml 
per minute per 1.73 m2) or serum CR 
alone (greater than 99 µmol per liter, or 
1.125 mg per deciliter). It is assumed that 
sickle cell/β-thalassemia, although gener-
ally a milder process than HbSS sickle cell 
disease, behaves similarly in the develop-
ment of a chronic nephropathy. This 
study helps to place the sickle cell disease 
patient into an appropriate time/event line 
(Figure 1) leading to kidney failure.
It has been clear that young sickle cell 
disease patients have a high glomerular 
fi ltration rate (GFR), which decreases 
over time in many. This loss of renal 
function may not be apparent, as CR is 
usually low. Of the 87 sickle cell/β-tha-
lassemia subjects, with an average age 
of 42.6 years, six had increased CR, 35 
had decreased CR clearance, and 28 had 
increased cystatin-C.2 Unfortunately, 
we do not know whether inhibition of 
tubular CR secretion might help correct 
the serum CR errors, nor how cystatin-C 
relates to true (iothalamate) GFR in this 
population, as they diverge in several 
contexts. If serum CR were to be used 
for GFR, sickle cell disease patients with 
diminished GFR would be erroneously 
assigned to stage 0 of kidney disease 
(http://www.Doqi.org) and be presumed 
to require attention more appropriate for 
later stages.
Beneath these errors in the estimation 
of GFR in sickle cell disease patients lie 
remarkable physiologic alterations. Nearly 
30 years ago, Statius van Eps, de Jong, and 
colleagues proposed that distinctive renal 
physiologic derangements in sickle cell 
disease might lead to a chronic glomerulo-
sclerosis, as they later summarized.3 Under 
favorable conditions, sickling causes 
vascular sludging, occlusion, and even 
infarction. In the kidney, the medullary 
area provides those conditions and, over 
time, develops a form of renal papillary 
necrosis. Although usually asymptomatic, 
renal papillary necrosis may be detectable 
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